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1 |  CASE
A 54- year- old man was diagnosed with MPL mutated, pri-
mary myelofibrosis in 2004 with a hypercellular marrow, 
MF- 2 fibrosis with megakaryocytic atypia, peripheral leu-
koerythroblastosis, splenomegaly, and an elevated lactate 
dehydrogenase. He was observed until 2010, when he was 
started on hydroxycarbamide for increasing symptoms. Prior 
to his 2011 enrollment in a clinical trial utilizing a novel 
JAK2 inhibitor, fedratinib, a bone marrow biopsy (Figure 1, 
Panel A; hematoxylin and eosin stain above, reticulin stain 
below, 10×) showed progressive megakaryocytic atypia and 
MF- 3 fibrosis. Nearly 1 year into the trial, a repeat bone mar-
row (Figure 1, Panel B; hematoxylin and eosin stain above, 
reticulin stain below, 20×) was hypocellular with MF- 3 fi-
brosis only in the cellular areas. The patient was taken off 
trial in 2013 and started on ruxolitinib. Repeat bone mar-
row biopsies in 2016 (Figure 1, Panel C; hematoxylin and 
eosin stain above, reticulin stain below, 10×) show a mar-
row comprised entirely of adipose tissue with osteosclerosis. 
Quantitative fat magnetic resonance (MR) imaging, utiliz-
ing methods reported separately,1 shows replacement of the 
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Key Clinical Message
Our case highlights a series of bone marrow biopsies from a patient with primary 
myelofibrosis. Over time, this patient developed an unusual fatty appearance to his 
marrow, confirmed on multiple biopsies. This finding was supported by a quantita-
tive fat MRI sequence that also shows a fatty appearance to the marrow.
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marrow with fat. Representative transaxial MR images of 
the pelvis show water- only, and fat- only (Figure 2, top row) 
constituents. Arrows show the iliac crests. A representative 
pseudocolor display that depicts 100% fat as dark red and 0% 
fat as dark blue is shown (Figure 2, bottom row). The per-
cent fat evident in the bone marrow imaging approximates 
that in the subcutaneous fat. After 3 bone marrow biopsies 
and the MR demonstrating this unusual transition of primary 
myelofibrosis to a fatty, aplastic appearing marrow, a repeat 
bone marrow in 2017 (Figure 1, Panel D; hematoxylin and 
eosin stain above, reticulin stain below, 20×) now showed a 
hypocellular marrow with histopathologic findings consis-
tent with his marrow at the time of diagnosis. To our knowl-
edge, this is the first case of a fibrotic marrow developing 
such an aplastic appearance in a patient treated with a JAK2 
inhibitor.
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F I G U R E  1  Histopathological findings from sequential bone marrow biopsies (panels A- D) of a patient with primary myelofibrosis that 
ultimately developed fatty replacement of his marrow. (H&E, top panels; Reticulin, bottom panels)
F I G U R E  2  Quantitative fat MRI 
shows replacement of bone marrow with fat. 
(Top row) Representative transaxial image 
of the pelvis shows water- only (left) and fat- 
only (only) acquisitions from a quantitative 
fat imaging sequence. Yellow arrows show 
iliac crests. (Bottom row) Images display the 
percent fat in each voxel with a grayscale 
display (right) or pseudocolor display that 
depicts 100% fat and 0% fat as red and dark 
blue, respectively (left). Percent fat in bone 
marrow approximates values measured in 
subcutaneous fat (orange arrow)
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